{"filter":{"phase":"PHASE3","status":null,"sponsor":null},"count":50,"items":[{"nct_id":"NCT07400653","brief_title":"A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Pfizer","lead_sponsor_class":"INDUSTRY","start_date":"2026-02-24","primary_completion_date":"2027-10-12","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07400653","external_url":"https://clinicaltrials.gov/study/NCT07400653"},{"nct_id":"NCT06924632","brief_title":"Efficacy & Safety of Minoxidil SL Tablets in Men With AGA","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"COMPLETED","lead_sponsor_name":"Samson Clinical Operations Pty Ltd","lead_sponsor_class":"INDUSTRY","start_date":"2025-07-14","primary_completion_date":"2026-05-15","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06924632","external_url":"https://clinicaltrials.gov/study/NCT06924632"},{"nct_id":"NCT06041217","brief_title":"A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"COMPLETED","lead_sponsor_name":"Novo Nordisk A/S","lead_sponsor_class":"INDUSTRY","start_date":"2023-09-15","primary_completion_date":"2025-04-02","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06041217","external_url":"https://clinicaltrials.gov/study/NCT06041217"},{"nct_id":"NCT06960213","brief_title":"STOP-HAE: A Phase 3 Study of ADX-324 in HAE","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"ADARx Pharmaceuticals, Inc.","lead_sponsor_class":"INDUSTRY","start_date":"2025-08-28","primary_completion_date":"2027-06-30","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06960213","external_url":"https://clinicaltrials.gov/study/NCT06960213"},{"nct_id":"NCT07592585","brief_title":"Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"NOT_YET_RECRUITING","lead_sponsor_name":"Jiangsu vcare pharmaceutical technology co., LTD","lead_sponsor_class":"INDUSTRY","start_date":"2026-05-30","primary_completion_date":"2028-05-30","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07592585","external_url":"https://clinicaltrials.gov/study/NCT07592585"},{"nct_id":"NCT05947851","brief_title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Merck Sharp & Dohme LLC","lead_sponsor_class":"INDUSTRY","start_date":"2023-08-08","primary_completion_date":"2032-06-01","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT05947851","external_url":"https://clinicaltrials.gov/study/NCT05947851"},{"nct_id":"NCT05096663","brief_title":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"SWOG Cancer Research Network","lead_sponsor_class":"NETWORK","start_date":"2022-03-15","primary_completion_date":"2027-06-30","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT05096663","external_url":"https://clinicaltrials.gov/study/NCT05096663"},{"nct_id":"NCT06357533","brief_title":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"AstraZeneca","lead_sponsor_class":"INDUSTRY","start_date":"2024-04-11","primary_completion_date":"2029-12-28","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06357533","external_url":"https://clinicaltrials.gov/study/NCT06357533"},{"nct_id":"NCT06980480","brief_title":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Takeda","lead_sponsor_class":"INDUSTRY","start_date":"2026-01-14","primary_completion_date":"2028-09-11","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06980480","external_url":"https://clinicaltrials.gov/study/NCT06980480"},{"nct_id":"NCT06990399","brief_title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Kodiak Sciences Inc","lead_sponsor_class":"INDUSTRY","start_date":"2025-07-30","primary_completion_date":"2027-04","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06990399","external_url":"https://clinicaltrials.gov/study/NCT06990399"},{"nct_id":"NCT05906758","brief_title":"Ultra-Low Contrast Angiography in AKI","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Tulane University","lead_sponsor_class":"OTHER","start_date":"2025-09-05","primary_completion_date":"2027-12","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT05906758","external_url":"https://clinicaltrials.gov/study/NCT05906758"},{"nct_id":"NCT07591077","brief_title":"SGLT2 Adjunct in T1D","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"COMPLETED","lead_sponsor_name":"Ain Shams University","lead_sponsor_class":"OTHER","start_date":"2024-11-20","primary_completion_date":"2025-11-20","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07591077","external_url":"https://clinicaltrials.gov/study/NCT07591077"},{"nct_id":"NCT01936272","brief_title":"Randomized Controlled Trial of Shunt vs ETV/CPC for PIH in Ugandan Infants","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"Boston Children's Hospital","lead_sponsor_class":"OTHER","start_date":"2013-05-27","primary_completion_date":"2026-06","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT01936272","external_url":"https://clinicaltrials.gov/study/NCT01936272"},{"nct_id":"NCT05535933","brief_title":"HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"Hutchmed","lead_sponsor_class":"INDUSTRY","start_date":"2022-09-30","primary_completion_date":"2025-11-25","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT05535933","external_url":"https://clinicaltrials.gov/study/NCT05535933"},{"nct_id":"NCT06678685","brief_title":"Spironolactone Improved Children With Gene Mutations Related to NCOR","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Qilu Hospital of Shandong University","lead_sponsor_class":"OTHER","start_date":"2024-10-30","primary_completion_date":"2026-12-30","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06678685","external_url":"https://clinicaltrials.gov/study/NCT06678685"},{"nct_id":"NCT07276724","brief_title":"A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Generate Biomedicines","lead_sponsor_class":"INDUSTRY","start_date":"2025-12-03","primary_completion_date":"2028-12","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07276724","external_url":"https://clinicaltrials.gov/study/NCT07276724"},{"nct_id":"NCT05630807","brief_title":"Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"COMPLETED","lead_sponsor_name":"GlaxoSmithKline","lead_sponsor_class":"INDUSTRY","start_date":"2022-12-07","primary_completion_date":"2025-11-11","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT05630807","external_url":"https://clinicaltrials.gov/study/NCT05630807"},{"nct_id":"NCT05536297","brief_title":"Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"COMPLETED","lead_sponsor_name":"Astellas Pharma Global Development, Inc.","lead_sponsor_class":"INDUSTRY","start_date":"2022-09-26","primary_completion_date":"2025-04-10","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT05536297","external_url":"https://clinicaltrials.gov/study/NCT05536297"},{"nct_id":"NCT06709014","brief_title":"A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"Annovis Bio Inc.","lead_sponsor_class":"INDUSTRY","start_date":"2025-02-04","primary_completion_date":"2027-12","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06709014","external_url":"https://clinicaltrials.gov/study/NCT06709014"},{"nct_id":"NCT07594158","brief_title":"A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Ono Pharmaceutical Co., Ltd.","lead_sponsor_class":"INDUSTRY","start_date":"2026-05-30","primary_completion_date":"2028-03-30","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07594158","external_url":"https://clinicaltrials.gov/study/NCT07594158"},{"nct_id":"NCT04857983","brief_title":"Memantine Augmentation of Targeted Cognitive Training in Schizophrenia","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"COMPLETED","lead_sponsor_name":"University of California, San Diego","lead_sponsor_class":"OTHER","start_date":"2021-07-06","primary_completion_date":"2025-03-30","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT04857983","external_url":"https://clinicaltrials.gov/study/NCT04857983"},{"nct_id":"NCT07067463","brief_title":"A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Zenas BioPharma (USA), LLC","lead_sponsor_class":"INDUSTRY","start_date":"2026-03-23","primary_completion_date":"2030-06","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07067463","external_url":"https://clinicaltrials.gov/study/NCT07067463"},{"nct_id":"NCT05892510","brief_title":"Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"University of Melbourne","lead_sponsor_class":"OTHER","start_date":"2024-06-01","primary_completion_date":"2027-08-30","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT05892510","external_url":"https://clinicaltrials.gov/study/NCT05892510"},{"nct_id":"NCT07462143","brief_title":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"RemeGen Co., Ltd.","lead_sponsor_class":"INDUSTRY","start_date":"2026-05-12","primary_completion_date":"2027-05-12","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07462143","external_url":"https://clinicaltrials.gov/study/NCT07462143"},{"nct_id":"NCT04370054","brief_title":"Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"Pfizer","lead_sponsor_class":"INDUSTRY","start_date":"2020-08-18","primary_completion_date":"2024-06-17","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT04370054","external_url":"https://clinicaltrials.gov/study/NCT04370054"},{"nct_id":"NCT07594119","brief_title":"Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"NOT_YET_RECRUITING","lead_sponsor_name":"Rapport Therapeutics Inc.","lead_sponsor_class":"INDUSTRY","start_date":"2026-05","primary_completion_date":"2029-07","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07594119","external_url":"https://clinicaltrials.gov/study/NCT07594119"},{"nct_id":"NCT07285239","brief_title":"Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"NOT_YET_RECRUITING","lead_sponsor_name":"PrECOG, LLC.","lead_sponsor_class":"OTHER","start_date":"2026-07","primary_completion_date":"2031-11","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07285239","external_url":"https://clinicaltrials.gov/study/NCT07285239"},{"nct_id":"NCT04965038","brief_title":"Early Reperfusion Therapy With Intravenous Thrombolysis for Recovery of VISION in Acute Central Retinal Artery Occlusion","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"TERMINATED","lead_sponsor_name":"University Hospital Tuebingen","lead_sponsor_class":"OTHER","start_date":"2022-10-10","primary_completion_date":"2026-03-23","why_stopped":"Stopped after prespecified interim analysis due to futility","last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT04965038","external_url":"https://clinicaltrials.gov/study/NCT04965038"},{"nct_id":"NCT07216482","brief_title":"A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Merck Sharp & Dohme LLC","lead_sponsor_class":"INDUSTRY","start_date":"2025-11-11","primary_completion_date":"2026-12-02","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07216482","external_url":"https://clinicaltrials.gov/study/NCT07216482"},{"nct_id":"NCT07593391","brief_title":"An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"NOT_YET_RECRUITING","lead_sponsor_name":"Neuren Pharmaceuticals Limited","lead_sponsor_class":"INDUSTRY","start_date":"2026-05-06","primary_completion_date":"2028-10-29","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07593391","external_url":"https://clinicaltrials.gov/study/NCT07593391"},{"nct_id":"NCT05211895","brief_title":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"AstraZeneca","lead_sponsor_class":"INDUSTRY","start_date":"2022-02-18","primary_completion_date":"2028-07-12","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT05211895","external_url":"https://clinicaltrials.gov/study/NCT05211895"},{"nct_id":"NCT06496178","brief_title":"A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Merus B.V.","lead_sponsor_class":"INDUSTRY","start_date":"2024-06-25","primary_completion_date":"2028-02","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06496178","external_url":"https://clinicaltrials.gov/study/NCT06496178"},{"nct_id":"NCT05221840","brief_title":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"AstraZeneca","lead_sponsor_class":"INDUSTRY","start_date":"2022-02-07","primary_completion_date":"2026-06-30","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT05221840","external_url":"https://clinicaltrials.gov/study/NCT05221840"},{"nct_id":"NCT07592273","brief_title":"Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"NOT_YET_RECRUITING","lead_sponsor_name":"AbbVie","lead_sponsor_class":"INDUSTRY","start_date":"2026-05-21","primary_completion_date":"2028-06","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07592273","external_url":"https://clinicaltrials.gov/study/NCT07592273"},{"nct_id":"NCT06237452","brief_title":"VE303 for Prevention of Recurrent Clostridioides Difficile Infection","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Vedanta Biosciences, Inc.","lead_sponsor_class":"INDUSTRY","start_date":"2024-05-20","primary_completion_date":"2027-06","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06237452","external_url":"https://clinicaltrials.gov/study/NCT06237452"},{"nct_id":"NCT06471257","brief_title":"A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"AstraZeneca","lead_sponsor_class":"INDUSTRY","start_date":"2024-06-17","primary_completion_date":"2026-10-30","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06471257","external_url":"https://clinicaltrials.gov/study/NCT06471257"},{"nct_id":"NCT07472491","brief_title":"A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"GE Healthcare","lead_sponsor_class":"INDUSTRY","start_date":"2026-04-01","primary_completion_date":"2027-11-30","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07472491","external_url":"https://clinicaltrials.gov/study/NCT07472491"},{"nct_id":"NCT06524544","brief_title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"National Cancer Institute (NCI)","lead_sponsor_class":"NIH","start_date":"2025-12-02","primary_completion_date":"2028-12-31","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06524544","external_url":"https://clinicaltrials.gov/study/NCT06524544"},{"nct_id":"NCT06660394","brief_title":"A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Longboard Pharmaceuticals","lead_sponsor_class":"INDUSTRY","start_date":"2024-09-25","primary_completion_date":"2026-08-21","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06660394","external_url":"https://clinicaltrials.gov/study/NCT06660394"},{"nct_id":"NCT06881992","brief_title":"A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Rezolute","lead_sponsor_class":"OTHER","start_date":"2025-04-16","primary_completion_date":"2027-09","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06881992","external_url":"https://clinicaltrials.gov/study/NCT06881992"},{"nct_id":"NCT04614714","brief_title":"Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"NOT_YET_RECRUITING","lead_sponsor_name":"University of California, Davis","lead_sponsor_class":"OTHER","start_date":"2026-06-01","primary_completion_date":"2026-06-30","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT04614714","external_url":"https://clinicaltrials.gov/study/NCT04614714"},{"nct_id":"NCT06757634","brief_title":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Celcuity Inc","lead_sponsor_class":"INDUSTRY","start_date":"2025-07-24","primary_completion_date":"2029-03-31","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06757634","external_url":"https://clinicaltrials.gov/study/NCT06757634"},{"nct_id":"NCT07593846","brief_title":"The Comparison Between DEDTI BR and T/E BR","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"NOT_YET_RECRUITING","lead_sponsor_name":"West China Hospital","lead_sponsor_class":"OTHER","start_date":"2026-05-01","primary_completion_date":"2028-12-31","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07593846","external_url":"https://clinicaltrials.gov/study/NCT07593846"},{"nct_id":"NCT04990128","brief_title":"Bone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"NOT_YET_RECRUITING","lead_sponsor_name":"The Cleveland Clinic","lead_sponsor_class":"OTHER","start_date":"2026-05-15","primary_completion_date":"2027-07","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT04990128","external_url":"https://clinicaltrials.gov/study/NCT04990128"},{"nct_id":"NCT06382012","brief_title":"Antiemetic Fosaprepitant To Remedy Nausea and Vomiting","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Montefiore Medical Center","lead_sponsor_class":"OTHER","start_date":"2024-11-13","primary_completion_date":"2027-03","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT06382012","external_url":"https://clinicaltrials.gov/study/NCT06382012"},{"nct_id":"NCT03808922","brief_title":"Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Ansun Biopharma, Inc.","lead_sponsor_class":"INDUSTRY","start_date":"2019-05-23","primary_completion_date":"2028-09-01","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT03808922","external_url":"https://clinicaltrials.gov/study/NCT03808922"},{"nct_id":"NCT07190248","brief_title":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Merck Sharp & Dohme LLC","lead_sponsor_class":"INDUSTRY","start_date":"2025-10-08","primary_completion_date":"2029-12-07","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT07190248","external_url":"https://clinicaltrials.gov/study/NCT07190248"},{"nct_id":"NCT03790293","brief_title":"Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the \"RITUXIMAB 3\" Trial","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"COMPLETED","lead_sponsor_name":"University Hospital, Rouen","lead_sponsor_class":"OTHER","start_date":"2018-11-17","primary_completion_date":"2019-04-19","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT03790293","external_url":"https://clinicaltrials.gov/study/NCT03790293"},{"nct_id":"NCT05293080","brief_title":"Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","lead_sponsor_class":"OTHER","start_date":"2025-11-06","primary_completion_date":"2031-07","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT05293080","external_url":"https://clinicaltrials.gov/study/NCT05293080"},{"nct_id":"NCT05591118","brief_title":"Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"NYU Langone Health","lead_sponsor_class":"OTHER","start_date":"2023-07-17","primary_completion_date":"2027-03-29","why_stopped":null,"last_update_date":"2026-05-18","url":"/api/v1/clinical/NCT05591118","external_url":"https://clinicaltrials.gov/study/NCT05591118"}]}